Evidence map›Paper›PMID 38782768›Full record

ArticleArchives of toxicology2024

Identifying novel mechanisms of per- and polyfluoroalkyl substance-induced hepatotoxicity using FRG humanized mice.

Dakota R Robarts, Diego Paine-Cabrera, Manasi Kotulkar, Kaitlyn K Venneman, Sumedha Gunewardena, Lander Foquet, Greg Bial, Udayan Apte

Abstract read
PubMed Publisher
In one paragraph

Article in Archives of toxicology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Dakota R RobartsDepartment of Pharmacology, Toxicology, and Therapeutics, University of Kansas Medical Center, 3901 Rainbow Blvd., MS1018, Kansas City, KS, 66160, USA.
Diego Paine-CabreraDepartment of Pharmacology, Toxicology, and Therapeutics, University of Kansas Medical Center, 3901 Rainbow Blvd., MS1018, Kansas City, KS, 66160, USA.
Manasi KotulkarDepartment of Pharmacology, Toxicology, and Therapeutics, University of Kansas Medical Center, 3901 Rainbow Blvd., MS1018, Kansas City, KS, 66160, USA.
Kaitlyn K VennemanDepartment of Pharmacology, Toxicology, and Therapeutics, University of Kansas Medical Center, 3901 Rainbow Blvd., MS1018, Kansas City, KS, 66160, USA.
Sumedha GunewardenaDepartment of Molecular and Integrative Physiology, University of Kansas Medical Center, Kansas City, KS, USA.
Lander FoquetYecuris Corporation, Tualatin, OR, USA.
Greg BialYecuris Corporation, Tualatin, OR, USA.
Udayan ApteDepartment of Pharmacology, Toxicology, and Therapeutics, University of Kansas Medical Center, 3901 Rainbow Blvd., MS1018, Kansas City, KS, 66160, USA. uapte@kumc.edu.ORCID 0000-0002-6741-7164

Funding

longitudinal assessment of stress and stress-related concepts across a behavioral weight loss interventionP20GM144269 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI Chelsea L Kracht, John P Thyfault · 2022 to 2026
$14.9M
THE ROLE OF HUMAN PXR IN ANTI-TUBERCULOSIS DRUG-INDUCED LIVER INJURYP20RR021940 · NCRR · UNIVERSITY OF KANSAS MEDICAL CENTER · PI KLASSEN, CURTIS D · 2006 to 2011
$12.1M
Nuclear Receptors in Liver Health and DiseaseP20GM103549 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI JAESCHKE, HARTMUT W. · 2012 to 2015
$8.1M
Using PCORnet to Expand the DS-CONNECT Cohort Through Healthcare System Recruitment, Incorporating Electronic Health Records, and Assessing Self-DeterminationU54HD090216 · NICHD · UNIVERSITY OF KANSAS LAWRENCE · PI COLOMBO, JOHN A. · 2016 to 2020
$6.2M
Molecular Regulation of Cell Development and Differentiation Phase III COBREP30GM122731 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI LITTLE, CHARLES D. · 2017 to 2021
$5.6M
Pilot Grants ProgramP30GM118247 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI JAESCHKE, HARTMUT W. · 2016 to 2020
$5.5M
Mechanisms of Liver Regeneration After Acetaminophen-Induced Acute Liver FailureR01DK098414 · NIDDK · UNIVERSITY OF KANSAS MEDICAL CENTER · PI APTE, UDAYAN · 2013 to 2023
$3.0M
High Throughput Sequencing System for KUMC Genomics CoreS10OD021743 · OD · UNIVERSITY OF KANSAS MEDICAL CENTER · PI SMITH, PETER G · 2017 to 2017
$493k
Role of HNF4alpha in Liver RegenerationR56DK112768 · NIDDK · UNIVERSITY OF KANSAS MEDICAL CENTER · PI APTE, UDAYAN · 2018 to 2018
$364k
NCRR NIH HHS P20 RR021940NIDDK NIH HHS R01 DK098414NIDDK NIH HHS R01 DK98414NIDDK NIH HHS R56 DK112768NIGMS NIH HHS P20 GM103549NIGMS NIH HHS P20 RR021940-03NIGMS NIH HHS P30 GM118247NIGMS NIH HHS P30 GM122731NIGMS NIH HHS S10 OD021743
6 · The paper itself

Abstract

Per- and polyfluoroalkyl substances (PFAS) such as perfluorooctanoic acid (PFOA) and perfluorooctane sulfonic acid (PFOS) and perfluoro-2-methyl-3-oxahexanoic acid (GenX), the new replacement PFAS, are major environmental contaminants. In rodents, these PFAS induce several adverse effects on the liver, including increased proliferation, hepatomegaly, steatosis, hypercholesterolemia, nonalcoholic fatty liver disease and liver cancers. Activation of peroxisome proliferator receptor alpha by PFAS is considered the primary mechanism of action in rodent hepatocyte-induced proliferation. However, the human relevance of this mechanism is uncertain. We investigated human-relevant mechanisms of PFAS-induced adverse hepatic effects using FRG liver-chimeric humanized mice with livers repopulated with functional human hepatocytes. Male FRG humanized mice were treated with 0.067 mg/L of PFOA, 0.145 mg/L of PFOS, or 1 mg/L of GenX in drinking water for 28 days. PFOS caused a significant decrease in total serum cholesterol and LDL/VLDL, whereas GenX caused a significant elevation in LDL/VLDL with no change in total cholesterol and HDL. All three PFAS induced significant hepatocyte proliferation. RNA-sequencing with alignment to the human genome showed a total of 240, 162, and 619 differentially expressed genes after PFOA, PFOS, and GenX exposure, respectively. Upstream regulator analysis revealed that all three PFAS induced activation of p53 and inhibition of androgen receptor and NR1D1, a transcriptional repressor important in circadian rhythm. Further biochemical studies confirmed NR1D1 inhibition and in silico modeling indicated potential interaction of all three PFAS with the DNA-binding domain of NR1D1. In conclusion, our studies using FRG humanized mice have revealed new human-relevant molecular mechanisms of PFAS including their previously unknown effect on circadian rhythm.

Indexed as

Alkanesulfonic AcidsCaprylatesChemical and Drug Induced Liver InjuryFluorocarbonsHepatocytesLiverAnimalsCell ProliferationEnvironmental PollutantsHumansMaleMiceMolecular Docking SimulationPPAR alphaAlkanesulfonic AcidsCaprylatesEnvironmental PollutantsFluorocarbonsperfluorooctane sulfonic acidperfluorooctanoic acidPPAR alphaCircadian rhythmGenXHumanized micePFASPFOAPFOSRNA-Seq

Identifiers

PMID38782768

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.